Cipla gets WHO nod to sell TB preventing drug in HIV patients
Cipla has received approval from WHO for Q-TIB, a combination drug to help prevent tuberculosis infection in people living with HIV
New Delhi: Drug major Cipla on Thursday said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV.
Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world. The company will market the product globally, Cipla said in a statement.
Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.
As per WHO’s Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.
Cipla shares were trading 1.31% down at Rs600.55 apiece on BSE on Thursday.
Editor's Picks »
- India’s renewable energy sector hits a milestone but loses speed
- All eyes now on share swap ratio in this mega bank merger
- Jet Privilege can actually get higher valuation than Jet Airways
- Profitability of cement firms to take a hit due to weak prices, high costs
- Pidilite’s shares hold their ground despite weak rupee and rising crude